Clinical Trial

A Study of CNCT19 in the Treatment of Relapsed or Refractory Neurological Autoimmune Diseases

Recruiting Early Phase 1
View on ClinicalTrials.gov →
Summary
This study is a single-arm, open-label, non-randomized clinical trial aimed at evaluating the safety, tolerability and preliminary efficacy of CNCT19 cell injection in the treatment of patients with relapsed/refractory Neurological Autoimmune Diseases.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-12-07; most recent amendment 2026-03-03.
Status change: Not Yet Recruiting → Recruiting 2026-03-03
Trial Details
NCT Number NCT07275736
Lead Sponsor Juventas Cell Therapy Ltd.
Collaborators: Beijing Tiantan Hospital
Conditions Neurological Autoimmune Diseases
Enrollment 18 participants
Start Date 2025-03-01
Primary Completion 2027-06-01 (estimated)
Study Completion 2029-06-01 (estimated)
Updated on ClinicalTrials.gov 2026-03-05